Literature DB >> 21538825

Sirolimus for refractory vascular anomalies.

Cameron C Trenor1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21538825     DOI： 10.1002/pbc.23178

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


× No keyword cloud information.
  3 in total

1.  Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma.

Authors:  Li Kai; Zuopeng Wang; Wei Yao; Kuiran Dong; Xianmin Xiao
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-25       Impact factor: 4.553

2.  Sirolimus for the treatment of children with various complicated vascular anomalies.

Authors:  Herwig Lackner; Anna Karastaneva; Wolfgang Schwinger; Martin Benesch; Petra Sovinz; Markus Seidel; Daniela Sperl; Sofia Lanz; Emir Haxhija; Friedrich Reiterer; Erich Sorantin; Christian E Urban
Journal:  Eur J Pediatr       Date:  2015-06-04       Impact factor: 3.183

3.  Efficacy and safety of sirolimus in the treatment of vascular malformations: A protocol for systematic review and meta-analysis.

Authors:  Jianyong Dong; Deting Han; Desheng Wang; Huijun Lu; Xiaoliang Wang
Journal:  Medicine (Baltimore)       Date:  2020-10-02       Impact factor: 1.817
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.